TrialInternational journal of clinical oncology2025

First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study.

Hisateru Yasui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.